Drug Resistance in Cancers
The NICB has developed a range of human cell models for resistance to chemotherapeutic agents (contact: Martin Clynes: firstname.lastname@example.org) and newer targeted therapeutics (contact: Norma O'Donovan: email@example.com), which are being used to discover novel therapeutic strategies to treat resistant cancers. We also have an active programme for detection of drug resistance-related proteins in human cancer tissue sections (contact: Annemarie Larkin: firstname.lastname@example.org).
- Stordal B, Hamon M, McEneaney V, Roche S, Gillet JP, O’Leary JJ, Gottesman M, Clynes M (2012) Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS One 7 (7): e40717.
- Muniyappa MK, Dowling P, Henry M, Meleady P, Doolan P, Gammell P, Clynes M, Barron N. (2009) MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines. Eur J Cancer. 45(17):3104-18
- Keenan J, Murphy L, Henry M, Meleady P, Clynes M (2009) Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line. Proteomics. 9(6):1556-66
- Kumar N, Gammell P, Meleady P, Henry M, Clynes M (2008) Differential protein expression following low temperature culture of suspension CHO-K1 cells. BMC Biotechnol. Apr 22; 8:42.